MAPT and neuroblastoma: As a potential alternate therapeutic strategy for reducing tau levels, or to further the understanding of novel pathways that modulate the expression or degeneration of tau, we performed a high throughput FACS based genome-wide CRISPR screen in a neuroblastoma cell line that expresses endogenous tau protein.